List of Rhopressa drug patents
Rhopressa is owned by Aerie Pharms Inc.
Rhopressa contains Netarsudil Mesylate.
Rhopressa has a total of 13 drug patents out of which 0 drug patents have expired.
Rhopressa was authorised for market use on 18 December, 2017.
Rhopressa is available in solution/drops;ophthalmic dosage forms.
Rhopressa can be used as reduction of elevated intraocular pressure.
Drug patent challenges can be filed against Rhopressa from December, 2021.
The generics of Rhopressa are possible to be released after 14 March, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8450344 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US9096569 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10654844 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US10174017 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US8394826 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(7 years from now) | |
| US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10532993 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11021456 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11028081 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(6 years from now) | |
| US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic